Skip to content
GSK
-
GSK acquires Rapt Therapeutics for USD2.2B to advance long-acting food allergy treatments
The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.
-
GSK expands its respiratory portfolio with FDA-approved long-acting biologic exdensur
The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.